Renal effects of molecular targeted therapies in oncology: A review by the Cancer and the Kidney International Network (C-KIN) Review uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Kidney Diseases
  • Protein Kinase Inhibitors

abstract

  • A number of cancer therapy agents are cleared by the kidney and may affect renal function, including cytotoxic chemotherapy agents, molecular targeted therapies, analgesics, antibiotics, radiopharmaceuticals and radiation therapy, and bone-targeted therapies. Many of these agents can be nephrotoxic, including targeted cancer therapies. The incidence, severity, and pattern of renal toxicities may vary according to the respective target of the drug. Here, we review the renal effects associated with a selection of currenty approved targeted cancer therapies, directed to vascular endothelial growth factor or VEGF receptor(s) (VEGF/VEGFR), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor2 (HER2), BRAF, anaplastic lymphoma kinase (ALK), programmed cell death protein-1 or its ligand (PD-1/PDL-1), receptor activator of nuclear factor kappa-B ligand (RANKL), and mammalian target of rapamycin (mTOR). The early diagnosis and prompt treatment of these renal alterations are essential in the daily practice where molecular targeted therapies have a definitive role in the armamentarium used in many cancers.

publication date

  • January 2015

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdv136

PubMed ID

  • 25735315

Additional Document Info

start page

  • 1677

end page

  • 84

volume

  • 26

number

  • 8